Literature DB >> 26692733

Imaging in Diabetic Retinopathy.

Jasmin Zvorničanin1, Edita Zvorničanin2.   

Abstract

Entities:  

Mesh:

Year:  2015        PMID: 26692733      PMCID: PMC4660548          DOI: 10.4103/0974-9233.167809

Source DB:  PubMed          Journal:  Middle East Afr J Ophthalmol        ISSN: 0974-9233


× No keyword cloud information.
Sir, We read with interest the excellent article by Salz and Witkin1 on imaging in diabetic retinopathy. We congratulate the authors on a thorough review and the clinical pearls and would like to make a contribution. The authors indicate that B-scan ultrasonography is most useful in patients with vitreous hemorrhage or other media opacity that precludes direct visualization of the retina during ophthalmic examination, but it is not particularly useful for imaging diabetic retinopathy if the media is clear.1 Furthermore, in studies analyzing various vitreoretinal disorders, the overall sensitivity of ultrasonography in identifying the anatomical position of the retina was 97.3–97.7%.23 However, in patients with more complex ultrasonography findings, such as tractional retinal detachment and choroidal detachment, the agreement between the ultrasonography and the surgical findings is slightly lower, between 92.2%3 and 92%,4 respectively. The main cause of misdiagnosis could be defined as the presence of multiple complicated echoes in eyes with tractional retinal detachment.2 However, ultrasonography examination can change the initial treatment plan in 4.8% and subclassify diagnosis and aid with further surgical planning in 13% of patients scheduled for pars plana vitrectomy.2 When considering only patients with poor visualization of the posterior segment, these figures are even higher at 9% and 20%, respectively.2 These outcomes are consistent with previous studies that reported ultrasonography established or changed the management plan in 8% and subclassified the diagnosis in 13% of patients with various posterior segment pathologies including cataract and choroidal detachment.5 Overall, we agree with Salz and Witkin that ultrasonography of the eye remains a useful part of the ophthalmic examination for detection and evaluation of vitreoretinal changes in patients with diabetic retinopathy.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  5 in total

1.  Comparison between clinical and ultrasound findings in patients with vitreous hemorrhage.

Authors:  R Rabinowitz; R Yagev; A Shoham; T Lifshitz
Journal:  Eye (Lond)       Date:  2004-03       Impact factor: 3.775

2.  Reliability of ocular ultrasonography findings for pre-surgical evaluation in various vitreo-retinal disorders.

Authors:  Swapnil Parchand; Ramandeep Singh; Swapnil Bhalekar
Journal:  Semin Ophthalmol       Date:  2014-01-10       Impact factor: 1.975

3.  Significance of ultrasonography in evaluation of vitreo-retinal pathologies.

Authors:  Jasmin Zvornicanin; Vahid Jusufovic; Emir Cabric; Zlatko Musanovic; Edita Zvornicanin; Allen Popovic-Beganovic
Journal:  Med Arch       Date:  2012

4.  The impact of echography on evaluation and management of posterior segment disorders.

Authors:  Ingrid U Scott; William E Smiddy; William J Feuer; Fiona J Ehlies
Journal:  Am J Ophthalmol       Date:  2004-01       Impact factor: 5.258

Review 5.  Imaging in diabetic retinopathy.

Authors:  David A Salz; Andre J Witkin
Journal:  Middle East Afr J Ophthalmol       Date:  2015 Apr-Jun
  5 in total
  2 in total

1.  Genetic and epigenetic modifications in the pathogenesis of diabetic retinopathy: a molecular link to regulate gene expression.

Authors:  Priya Pradhan; Nisha Upadhyay; Archana Tiwari; Lalit P Singh
Journal:  New Front Ophthalmol       Date:  2016-10-24

2.  Curcumin inhibits high glucose‑induced inflammatory injury in human retinal pigment epithelial cells through the ROS‑PI3K/AKT/mTOR signaling pathway.

Authors:  Zhenlong Ran; Yueling Zhang; Xiaoying Wen; Jingxue Ma
Journal:  Mol Med Rep       Date:  2018-12-12       Impact factor: 2.952

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.